

**PE/Cy5 anti-mouse CD135**

**Catalog # / Size:** 1276555 / 25 µg  
1276560 / 100 µg

**Clone:** A2F10

**Isotype:** Rat IgG2a, κ


**Immunogen:** Mouse Flt3 transfected cell line

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2




C57BL/6 bone marrow cells stained with A2F10 PE/Cy5 and CD45R/B220 +CD11b APC

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 microg per 10<sup>6</sup> cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.



C57BL/6 bone marrow cells stained with rat IgG2a PE/Cy5 isotype control and CD45R/B220 + CD11b APC

**Application References:** 1. Sergejeva S, *et al.* 2004. *Blood* 103:1270.  
2. Auffray C, *et al.* 2009. *J. Exp. Med.* 206:595.

**Description:** CD135, also known as Flk-2, Flt3, and Ly-72, is a type III tyrosine kinase receptor. It is expressed on early B lymphoid lineage cells in bone marrow, on primitive myeloid progenitors within the BM CD34+ cell population. Ligation of Flk-2 with Flt3 ligand regulates the growth of hematopoietic stem cells and promotes the survival of primitive hematopoietic progenitor cells with myeloid as well as B lymphoid potential. It was reported that the receptor tyrosine kinase Flt3 is required for dendritic cell development. Combined signaling through interleukin-7 receptors and Flt3 selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells.

**Antigen References:** 1. Waskow C, *et al.* *Nat. Immunol.* 9:676  
2. Veiby OP, *et al.* 1996. *Blood* 88(4):1256  
3. Veiby OP, *et al.* 1996. *J. Immunol.* 157(7):2953  
4. Matthews W, *et al.* 1991. *Cell.* 65(7):114

